Outlook Therapeutics, Inc. (OTLK)
0.6405
-0.03
(-3.90%)
USD |
NASDAQ |
Sep 08, 16:00
0.6447
0.00 (0.00%)
Pre-Market: 08:35
Outlook Therapeutics Total Assets (Quarterly) : 26.18M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 26.18M |
| March 31, 2026 | 21.89M |
| December 31, 2025 | 18.24M |
| June 30, 2025 | 22.39M |
| March 31, 2025 | 19.08M |
| December 31, 2024 | 17.01M |
| September 30, 2024 | 28.82M |
| June 30, 2024 | 47.09M |
| March 31, 2024 | 59.03M |
| December 31, 2023 | 21.68M |
| September 30, 2023 | 32.30M |
| June 30, 2023 | 44.45M |
| March 31, 2023 | 54.02M |
| December 31, 2022 | 62.69M |
| September 30, 2022 | 28.53M |
| June 30, 2022 | 38.59M |
| March 31, 2022 | 67.69M |
| December 31, 2021 | 78.68M |
| September 30, 2021 | 22.81M |
| June 30, 2021 | 32.88M |
| March 31, 2021 | 45.11M |
| Date | Value |
|---|---|
| December 31, 2020 | 12.52M |
| September 30, 2020 | 19.73M |
| June 30, 2020 | 30.24M |
| March 31, 2020 | 13.17M |
| December 31, 2019 | 10.42M |
| September 30, 2019 | 17.14M |
| June 30, 2019 | 33.21M |
| March 31, 2019 | 17.17M |
| December 31, 2018 | 18.71M |
| September 30, 2018 | 22.28M |
| June 30, 2018 | 34.09M |
| March 31, 2018 | 27.79M |
| December 31, 2017 | 32.28M |
| September 30, 2017 | 20.73M |
| June 30, 2017 | 17.13M |
| March 31, 2017 | 17.46M |
| December 31, 2016 | 20.45M |
| September 30, 2016 | 23.71M |
| June 30, 2016 | 32.99M |
| March 31, 2016 | 24.83M |
| December 31, 2015 | 31.32M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Valion Bio, Inc. | 32.47M |
| Agenus, Inc. | 172.69M |
| Amgen, Inc. | 95.64B |
| Anika Therapeutics, Inc. | 183.47M |
| BioCryst Pharmaceuticals, Inc. | 557.85M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 36.58M |
| Shareholders Equity (Quarterly) | -10.39M |
| Debt to Equity Ratio | -1.774 |
| Current Ratio | 0.8078 |
| Net Debt Paydown Yield | 0.85% |